1 / 8

R&I: Systemic Psoriasis Therapeutics Market 2020

GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. T Detailed report at: http://www.reportsandintelligence.com/systemic-psoriasis-therapeutics-in-major-developed-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market

SarahPalin111
Download Presentation

R&I: Systemic Psoriasis Therapeutics Market 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Publisher: GBI Research No of pages: 101 Publish Date: Feb 2014

  2. Description GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

  3. Scope • An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment • Analysis of the major systemic therapies in the current psoriasis marketed landscape • Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided. • Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.

  4. Reasons to buy • Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved • Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted • Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages • Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets • Request for discount at: http://www.reportsandintelligence.com/purchase-enquiry/132420

  5. Table Of Content 1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 Overview 82.2 Epidemiology 92.3 Etiology, Co-morbidities and Risk Factors 102.3.1 Genetics 102.3.2 Psoriatic Arthritis 102.3.3 Mental Health Disorders 112.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 112.3.5 Infections 112.3.6 Köebner Phenomenon 122.3.7 Other Immune-mediated Diseases 122.4 Pathophysiology 122.5 Diagnosis 13

  6. Table Of Content 2.6 Treatment Options 132.6.1 Pharmacological Therapies 142.6.2 Non-pharmacological Therapies 152.6.3 Combination and Rotational Therapies 152.6.4 Quality of Life Assessments 162.7 Summary 163 Marketed Products 173.1 Overview 173.2 Methotrexate-based Products 173.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) - Novartis 183.4 Soriatane (acitretin) - Steifel Laboratories 193.5 Fumaderm (dimethyl fumarate and ethyl fumarate) - Biogen Idec 203.6 Humira (adalimumab) - Abbvie Inc. 213.7 Enbrel (etanercept) - Amgen Inc. 223.8 Remicade (infliximab) - Janssen Biotech 233.9 Stelara (ustekinumab) - Janssen Biotech 24 3.10 Marketed Products Heat Map 25

  7. Table Of Content 4 Pipeline 284.1 Overview 284.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type 294.3 Pipeline Distribution by Molecular Target 314.4 Clinical Trial Landscape 334.4.1 Clinical Trial Duration 334.4.2 Clinical Trial Size 374.5 Clinical trial failure rates 414.6 Primary and Secondary Endpoints 424.7 Summary of Psoriasis Clinical Trials 444.8 Promising pipeline molecules 44 Get full TOC at: http://www.reportsandintelligence.com/systemic-psoriasis-therapeutics-in-major-developed-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market/table-of-contents

  8. FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/systemic-psoriasis-therapeutics-in-major-developed-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: sales@reportsandintelligence.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States

More Related